1 – 8 of 8
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
2024) In Molecular Oncology(
- Contribution to journal › Article
- 2021
-
Mark
Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations
(
- Contribution to journal › Article
- 2020
-
Mark
Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR)
(
- Contribution to journal › Article
- 2014
-
Mark
A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer
(
- Contribution to journal › Article
- 2012
-
Mark
The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer Results from the Nordic ACT trial
(
- Contribution to journal › Article
-
Mark
Using intravital microscopy to observe bevacizumab-mediated anti-angiogenesis in human head and neck squamous cell carcinoma xenografts
(
- Contribution to journal › Article
-
Mark
Bevacizumab in the treatment of ovarian cancer
(
- Contribution to journal › Scientific review
- 2010
-
Mark
Electrophysiological Assessment of Retinal Function During 6 Months of Bevacizumab Treatment in Neovascular Age-Related Macular Degeneration
(
- Contribution to journal › Article